Insilico Medicine's lead drug, INS018_055, reached Phase II trials in 2026, marking it as the first generative AI-designed drug for an AI-discovered target to achieve this milestone. Insilico Medicine's lead drug, INS018_055, reaching Phase II trials in 2026 offers a glimpse into how artificial intelligence accelerates the search for new therapies, potentially shortening timelines for patients awaiting critical treatments. SK Biopharmaceuticals has also developed its own big data and AI-based drug design platform, alongside a genomic analysis platform, validating the broader industry trend towards AI-driven discovery.
Despite this groundbreaking progress, a significant disconnect persists in the broader life sciences industry. Over 60% of life science labs are still only exploring or piloting AI, with a mere 5% using AI agents in full production. Over 60% of life science labs still only exploring or piloting AI, with a mere 5% using AI agents in full production, creates a tension between frontier innovation and widespread practical application.
The gap between AI's proven potential in accelerating drug discovery and its practical, widespread implementation in labs is likely to widen, creating a two-tiered system in pharmaceutical innovation. The gap between AI's proven potential in accelerating drug discovery and its practical, widespread implementation in labs, likely to widen and create a two-tiered system in pharmaceutical innovation, suggests that while advanced AI platforms drive breakthroughs for some, many organizations struggle with foundational integration.
Where Labs Prioritize AI Today
- Researchers prioritize AI for data analysis, workflow automation, experiment design, and sample management, according to Selectscience.
Labs prioritize AI for its immediate value in streamlining critical lab functions, particularly in data-intensive tasks. Labs prioritizing AI for its immediate value in streamlining critical lab functions, particularly in data-intensive tasks, aims to enhance efficiency and accuracy across various stages of drug discovery and development, directly impacting project timelines and resource allocation.
Generative AI Moves to Production in Key Lab Functions
LabGenius and LG Chem have entered into a research collaboration, according to Drug Target Review. LabGenius and LG Chem's research collaboration signals a strategic shift towards operationalizing advanced AI in drug development. While AI agents see limited full production use, generative AI is more widely adopted for specific functions. A notable 57% of labs use AI for data analysis, and 25% report using generative AI in full production, according to Selectscience. A notable 57% of labs using AI for data analysis, and 25% reporting generative AI in full production, according to Selectscience, indicates a distinction: generative AI is applied for specific tasks, while fully autonomous 'AI agents' represent a higher bar for deployment, often requiring more robust infrastructure and trust.
The Gap Between Exploration and Production
A January 2026 survey of 113 life sciences professionals reveals over 60% of labs are exploring or piloting AI, with most deployments remaining experimental. A January 2026 survey of 113 life sciences professionals revealing over 60% of labs are exploring or piloting AI, with most deployments remaining experimental, highlights a significant gap between aspiration and widespread production, suggesting that initial enthusiasm often stalls at the proof-of-concept stage. Despite broad interest, only 5% of labs use AI agents in full production. Only 5% of labs using AI agents in full production, contrasted with Insilico Medicine's groundbreaking AI-designed drug reaching Phase II trials, indicates a widening chasm: a select few are leveraging AI for true innovation and accelerated discovery, while the vast majority struggle with foundational AI implementation, risking obsolescence and a permanent lag in the race for new therapies.
The Rise of Agentic AI Solutions
The market is seeing the emergence of specialized agentic AI solutions, with Technology listing the top 7 expected in 2026. The emergence of specialized agentic AI solutions, with Technology listing the top 7 expected in 2026, positions AI for a more sophisticated and autonomous role in drug discovery. The implication is that these advanced systems will not only streamline complex processes but also further stratify the industry, favoring those capable of integrating and leveraging such cutting-edge autonomy.
Addressing Practical Challenges for AI Adoption
What are the challenges of implementing AI in drug discovery?
Companies failing to prioritize LIMS, ELN, and instrument integration are effectively building a moat against advanced AI adoption. Connectivity and integration are top investment priorities for labs, with 62% of small and medium-sized organizations prioritizing these aspects, according to Selectscience. Companies failing to prioritize LIMS, ELN, and instrument integration ensures their labs remain stuck in experimental phases while competitors accelerate.
How is AI transforming lab automation in life sciences?
AI is transforming lab automation by enabling more efficient data analysis, workflow automation, and experiment design. However, the full impact is hindered by integration challenges, as only 5% of labs use AI agents in full production, according to Selectscience. Addressing these foundational infrastructure issues is critical for widespread transformation.
If current integration challenges persist, the pharmaceutical landscape will likely bifurcate, with a few AI-native pioneers outpacing traditional labs in drug development speed and innovation.
